PHIO
PHIO clinical trials: Phio Pharmaceuticals Corp.
Every trial on ClinicalTrials.gov where Phio Pharmaceuticals Corp. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PHIO on the catalyst calendar · PHIO registry changes
- Primary completion Dec 29, 2025ActualPhase 1NCT06014086Intratumoral PH-762 for Cutaneous CarcinomaPhio Pharmaceuticals Inc. · Squamous Cell Carcinoma of the SkinCompletedPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2018Sponsor estimatePhase 1/Phase 2NCT02599064Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMDRXi Pharmaceuticals, Corp. · Age-related Macular DegenerationUnknown statusPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2018ActualPhase 2NCT02640820Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)RXi Pharmaceuticals, Corp. · Common WartsUnknown statusPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2017ActualPhase 2NCT02246465A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic ScarsRXi Pharmaceuticals, Corp. · Hypertrophic ScarUnknown statusPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 2NCT02030275A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy AdultsRXi Pharmaceuticals, Corp. · Hypertrophic ScarCompletedPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2016ActualPhase 2NCT02079168A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy AdultsRXi Pharmaceuticals, Corp. · KeloidCompletedPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2014ActualPhase 1NCT01780077Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109RXi Pharmaceuticals, Corp. · CicatrixCompletedPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualPhase 1NCT01640912Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109RXi Pharmaceuticals, Corp. · CicatrixCompletedPHIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT05902520Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid TumorsAgonOx, Inc. · HNSCCActive, not recruitingPHIOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner